Life Science News

Optimi Health Corp. ( CSE: OPTI ) (OTCQX: OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), a Canadian-based company licensed by Health Canada to produce natural, scalable, and accessible psychedelic and functional mushrooms for transformational human experiences, is pleased to announce that it has entered into its first international psilocybin supply agreement with Promises Innovative Recovery ("PIR").

Through founders Pamela and Gary Roberts, the renowned Florida-based Social Impact Organization provides expert substance abuse, addiction, and mental health services to treatment centers through its comprehensive and exceptional intensive outpatient protocol.

Further, PIR is a globally minded medical, research, and educational center focusing on preventative healthcare, precision medicine, and innovative treatments, including psychedelic-assisted psychotherapy and plant-based therapeutics.

The Company, along with licensed cannabis producer Castle Rock Farms Inc ., a Princeton, British Columbia-based subsidiary of BC Green Pharmaceuticals Inc . (‘BC Green'), will be collaborating with PIR and Knowde Group, Inc. , a Global Contract Research Organization and Life Sciences Consultancy, on the establishment of a Center of Excellence in Costa Rica devoted to scientific research, therapeutic discovery, and advancing techniques in psychedelic-assisted mental health treatments utilizing both cannabis and psilocybin.

Following recent regulatory advancements in Costa Rica surrounding the medicalization of cannabis, Optimi is pleased to support PIR's work with the Costa Rican government to establish a medicinal and therapeutic psychedelic research framework in collaboration with public and private sector stakeholders.

"The need for a safe, consistent supply of psilocybin for scientific research and better health outcomes are not limited to Canada," said Optimi Health CEO Bill Ciprick. "As we look to the international research and commercial landscape for psilocybin, we are now presented with the opportunity to both supply and participate in the establishment of a ground-breaking research center whose work will translate to very real, lived advancements in patient care."

Bryan Safarik, Chief Operations Officer of BC Green, added that "the leadership of the Costa Rican government, and Promises Innovative Recovery, is an excellent chance for industry stakeholders to move forward in partnership and good faith with national health authorities. It is our sincere hope that this collaboration, beginning with research and medical tourism, will lead to a more complete regulatory framework for the widespread medicinal implementation of cannabis and psychedelic therapeutics."

Promises Innovative Recovery Co-Founder, Gary Roberts, is meeting with Costa Rican officials and interested stakeholders this week to discuss the licensed framework.

"Our agreement with Optimi and BC Green instantly validates the quality and scale of supply required to support a future medicinal and therapeutic framework in Costa Rica," said Roberts.

Roberts also lauded Optimi and BC Green's expertise working within Health Canada's Special Access Programme (SAP), a regulated model accessed by Canadians facing serious or life-threatening illnesses.

"We have an opportunity to build a clinically validated, compassionate access framework, much like the SAP model in Canada, that would put Costa Rica's psychedelic medical tourism industry in a league of its own. Our strategic partners, Knowde Group, are leaders in this sector and will be providing the clinical and regulatory guidance to accomplish this. There are tremendous benefits in this space, and we are looking forward to exploring them together."

Appointment of Chief Science Officer

Optimi is pleased to announce the appointment of Chief Science Officer, Mr. Justin Kirkland , to the PIR Medical & Clinical Advisory Board. Justin will join a team of leading experts in the development of treatment protocols, identify research priorities, and help form the broader group of advisors and on site medical team.

Authorized parties interested in purchasing or distributing Optimi psilocybin and functional mushroom products, MDMA, or other synthetic psychedelics are invited to contact sales@optimihealth.ca, where a member of the sales team will respond within 24 hours.

FOR INTERVIEW REQUESTS OR FURTHER INFORMATION, PLEASE CONTACT:

Michael Kydd
Investor Relations
Email: investors@optimihealth.ca
Phone: +1 (902) 880 6121
Web: www.optimihealth.ca

ABOUT OPTIMI (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN)

Optimi Health Corp. is a Canadian-based company licensed by Health Canada to produce and supply natural, EU-GMP grade psilocybin and other psychedelic substances, as well as functional mushrooms that focus on the health and wellness markets. Built with the purpose of producing scalable psychedelic formulations for transformational human experiences, the Company's goal is to be the number one trusted, compassionate supplier of safe drug products throughout the world. Optimi's products are grown at its two facilities comprising a total of 20,000 square feet in Princeton, British Columbia, making it the largest psilocybin and MDMA cultivator in North America.

ABOUT BC GREEN PHARMACEUTICALS INC.

BC Green is a farm, family, and brand operating in the beautiful Okanagan-Similkameen Valley. With its specialized cultivation facility based in Princeton, B.C., christened ‘Castle Rock Farms,' BC Green is on a mission to transform the legal cannabis market through the cultivation of a diverse range of Premium-Grade, GMP-certified cannabis, offering industry-leading quality to clients and partners.

ABOUT PROMISES INNOVATIVE RECOVERY

Founded by Gary and Pamela Roberts, Promises Innovative Recovery was established to provide innovative therapies, including plant-based medicine and psychedelic-assisted psychotherapy, to support patients in their recovery journey from mental health conditions, brain injuries, and addictions. PIR offers end-to-end support for community members, including medical delivery of innovative therapeutics, facilities for licensing entities conducting clinical trials, and education for medical professionals with the opportunity for hands-on training.

ABOUT KNOWDE GROUP, INC.

Knowde Group, Inc. is a female founded and led, hybrid Global Contract Research Organization and Life Sciences Consultancy committed to the advancement of emerging biotech and progressive therapeutics™. Incorporated in Canada and the United Kingdom, Knowde Group is a leader in cannabinoid and psychedelics research and project development. With support ranging from preclinical modelling, access to capital, Phase I – IV clinical trials and commercialization, Knowde Group understands the unique needs of novel life science and technology companies navigating today's competitive market. Knowde Group is proud to be Promises Innovative Recovery's Strategic Partner in the development and execution of this project.

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/a0601030-ddbc-45a9-bb30-f07d9f044c5c

https://www.globenewswire.com/NewsRoom/AttachmentNg/5deef40c-12b6-4057-97a5-25042ec67df2

https://www.globenewswire.com/NewsRoom/AttachmentNg/19dfa03a-dbae-48ec-9ce6-3f4f613c6bcd


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

OPTI:CC
Optimi Health

Optimi Health


Keep reading...Show less
Optimi Health, ATMA Journey Centers To Proceed With Phase I Natural Psilocybin and MDMA Clinical Trial Application to Health Canada

Optimi Health, ATMA Journey Centers To Proceed With Phase I Natural Psilocybin and MDMA Clinical Trial Application to Health Canada

Optimi Health Corp . ( CSE: OPTI ) (OTCQX: OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), a Canadian-based company licensed by Health Canada to produce and supply natural, EU-GMP grade psilocybin and other psychedelic substances, most notably MDMA, is pleased to announce that in conjunction with ATMA Journey Centers ("ATMA"), the companies have confirmed their intent to proceed with a Phase I clinical trial application (CTA) that will document the safety of the Optimi's natural psilocybin biomass and 3,4-methylenedioxy-methamphetamine (MDMA) in healthy patients.

Upon Health Canada approval, it would be the first trial to assess both safety and additional markers, such as the mystical experience questionnaire in healthy subjects that have consumed MDMA.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Optimi Health Completes Largest Legal Natural Psilocybin Harvest in Canadian History

Optimi Health Completes Largest Legal Natural Psilocybin Harvest in Canadian History

Optimi Health Corp. ( CSE: OPTI ) (OTCQX: OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), is pleased to announce that it has completed what it believes to be the largest legal natural psilocybin harvest in Canadian history. The Company is licensed by Health Canada to produce and supply natural, EU-GMP grade psilocybin and other psychedelic substances, most notably MDMA, as well as functional mushrooms that focus on the health and wellness markets.

Building off its first official harvest on May 27 th , which produced various strains of psilocybin for lab analysis and early-stage supply agreements, the Company is pleased to report that its investment in state-of-the art environmental controls and facility cultivation operations have resulted in a commercially harvested yield of more than 150 kg of Panaeolus cyanescens and Psilocybe cubensis.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Optimi Health Signs First International Mushroom Supply Agreement with UK-based Avida Global

Optimi Health Signs First International Mushroom Supply Agreement with UK-based Avida Global

Optimi Health Corp. ( CSE: OPTI ) (OTCQX: OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), a Canadian-based company licensed by Health Canada to produce natural, scalable, and accessible psychedelic and functional mushroom products for transformational human experiences, is pleased to announce that it has entered into an agreement with Avida Global ("Avida"), a privately-held UK-based producer of high-quality wellness products, including nutraceuticals and medicinal cannabis oils, for the global well-being and medical markets.

In its first large-scale international distribution agreement, Optimi will supply Avida with an extensive catalog of Optimi Life functional mushroom supplement formulations. The supplements will be available for distribution to clients and partners worldwide via Avida Labs, Avida's white-labelling and manufacturing business.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Optimi Health Provides Progress Report On Year Of Commercialization

Optimi Health Provides Progress Report On Year Of Commercialization

Company set to introduce psychedelic product catalogue showcasing in-house EU-GMP manufacturing expertise

Optimi Health Corp. ( CSE: OPTI ) (OTCQX: OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), a Canadian-based company licensed by Health Canada to produce and supply natural, EU-GMP grade psilocybin and synthetic psychedelic substances, as well as functional mushrooms that focus on the health and wellness markets, is pleased to provide an operational update on the progress of its planned year of commercialization.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Optimi Health Announces Canadian Retail and E-Commerce Distribution Agreements for Functional Mushroom Supplements and Appoints Chief Financial Officer to its Board of Directors

Optimi Health Announces Canadian Retail and E-Commerce Distribution Agreements for Functional Mushroom Supplements and Appoints Chief Financial Officer to its Board of Directors

Optimi Health Corp. ( CSE: OPTI ) (OTCQX: OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), a Canadian-based company licensed by Health Canada to produce natural, scalable, and accessible psychedelic and functional mushrooms for transformational human experiences, is pleased to announce that it has finalized three new Canadian retail and e-commerce distribution agreements for its Optimi Life nutraceutical mushroom products.

The agreements with Well.ca, Vitasave, and Healthy Planet come within six months of the Company's February launch of Optimi Life ( www.optimilife.com ), a line of functional mushroom supplements transforming the industry with formulations made from the highest possible quality fruiting body mushrooms for whole body and mind optimization.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Lobe Sciences Announces Incorporation of Australian Subsidiary

Lobe Sciences Announces Incorporation of Australian Subsidiary

 lobe sciences ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced it has incorporated Lobe Sciences Australia Pty Ltd., a 100% owned Australian subsidiary of the Company, to facilitate the three or more clinical trials in Australia with newly announced partner iNGENū Pty Ltd. The trials aim to evaluate Lobe's proprietary psilocin analogues L-130 or L-131. Australian Federal Government's Research & Development tax incentive program will provide rebates to Lobe for up to 43.5% on eligible expenditures for Research and Development conducted in Australia. The clinical trials are expected to commence in late 2022 or early 2023 pending local Regulatory approval.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Nirvana Life Sciences Inc. Deuterates 7-Hydroxymitragynine to Create D7-h, an Analogue that May Improve Research and Formulations using Kratom Derivatives

Nirvana Life Sciences Inc. Deuterates 7-Hydroxymitragynine to Create D7-h, an Analogue that May Improve Research and Formulations using Kratom Derivatives

Nirvana Life Sciences Inc. (Nirvana or the "Company") (CSE: NIRV) a western Canadian based life sciences company aimed at developing psychedelic therapeutic medicines, including non-addictive chronic pain and relapse preventing products is pleased to report filing of a patent for D7-h.

Nirvana Life Sciences Inc. Logo (CNW Group/Nirvana Life Sciences Inc.)

Nirvana Life Sciences Inc. is pleased to announce it has recently filed a patent for the deuterated form of 7-hydroxymitragynine (D7-h), the active compound in kratom responsible for the opiate like effect the plant produces when ingested. Opioid use disorder and opioid addiction remain at epidemic levels in Canada , the US and worldwide.  In 2021, there were 7560 apparent opioid-related deaths in Canada , which is equivalent to 20 people dying each day, and was greater than the average number of Canadians killed daily in motor vehicle collisions. This number continues to grow, with the PHAC projecting as many as 2400 opioid-related deaths in each quarter of 2022.

The use of Kratom in Southeast Asia has been documented back for at least 150 years and is described both as having a stimulant effect for use in hard day labor when fresh leaves are chewed and an analgesic and relaxing effect if brewed into a tea. In the past decade or more, recognition and the use of kratom has grown in Canada , the United States , and the world at large. Although use has increased, there still remains a lack of research regarding kratom and the various different components within it that are active when taken. One important observation that has been made is that people who take kratom do not see the same respiratory decrease that is often the cause of death and overdose in people who take opiates. This is due to 7-hydroxymitragynine being a partial mu opioid agonist, unlike Fentanyl and oxycodone which are full mu opioid agonists and are known to have depressant effects on respiration.

With so many people affected by opioid use disorder, opioid addiction, and the risk of death from using these substances, research into alternative pain formulations is more than ever necessary. In order to create a medicine that has the potential to truly help people with addictions and those living with chronic pain, it is important to have a deep understanding of how these compounds work in the brain and body. Scientists and doctors have long used deuterated drugs to help track how a drug moves through the brain and body, in order to gain a better understanding of its mechanisms.

A deuterated drug is a small molecule medicinal product in which one or more of the hydrogen atoms contained in the drug molecule have been replaced by its heavier stable isotope deuterium. Because of the kinetic isotope effect, deuterium-containing drugs may have significantly lower rates of metabolism, and hence a longer half-life, as can be seen with Deutetrabenazine, a deuterated version of tetrabenazine, developed by Teva and approved by the FDA in 2017 for the treatment of chorea associated with Huntington's disease. Applications of the deuterium isotope effect have increased over time, and it is now applied extensively in mechanistic research focused on the metabolism of drugs, as well as with many other studies that focus on safety, efficacy, tolerability, bioavailability, and pharmacokinetics (PK).

Nirvana Life Sciences Inc. knows the importance of creating a deuterated form of 7-hydroxymitragynine (D7-h) in order to gain a better understanding of the mechanisms of this compound in the body, including knowledge about safety, bioavailability, efficacy, pharmacokinetics (PK) and more. It is our hope that researchers at Nirvana Life Sciences Inc. and elsewhere will be able to use D7-h to fill the gap in knowledge that exists about kratom, to then create safer and more effective alternatives to opiates for people struggling with addiction and chronic pain.

Robert August , lead chemist and Head of Innovation with Nirvana Life Sciences Inc., stated "With research in chronic pain and addiction, and developing treatments for these, being at the forefront of the mission of Nirvana Life Sciences Inc., we are hopeful to see how this development may change not just science, but the lives of many people." We couldn't agree more and are thrilled to add D7-h to our growing portfolio of novel compounds, formulations and processes focused on chronic pain, addiction and trauma.

Nirvana Life Sciences Inc. has been founded with a simple objective of researching and developing non-addictive pain management and relapse prevention products that can provide healthier outcomes for patients who live with chronic pain and/or have battled with addiction. Nirvana believes that using naturally sourced psychedelics in novel formulations holds the promise of delivering non-addictive solutions that are effective in managing pain and addiction. Nirvana's team, consisting of leading researchers from around the globe, will develop therapies that have the potential of freeing millions from addiction and saving society billions of dollars annually

Forward Looking Statements

This news release contains certain forward-looking statements and forward-looking information (collectively referred to herein as "forward-looking statements") within the meaning of Canadian securities laws including, without limitation, statements with respect to the future investments by the Company. All statements other than statements of historical fact are forward-looking statements. Undue reliance should not be placed on forward-looking statements, which are inherently uncertain, are based on estimates and assumptions, and are subject to known and unknown risks and uncertainties (both general and specific) that contribute to the possibility that the future events or circumstances contemplated by the forward-looking statements will not occur. Although the Company believes that the expectations reflected in the forward-looking statements contained in this press release, and the assumptions on which such forward-looking statements are made, are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements included in this document, as there can be no assurance that the plans, intentions or expectations upon which the forward-looking statements are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause the Company's actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, except as required by applicable law. The forward-looking statements contained herein are expressly qualified by this cautionary statement.

SOURCE Nirvana Life Sciences Inc.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/September2022/22/c3080.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Love Pharma Launches Proprietary E-Commerce Platform for Online Sales

Love Pharma Launches Proprietary E-Commerce Platform for Online Sales

  • LOVE's online store launches with fully integrated e-commerce platform
  • Consumers can now purchase the Company's two proprietary branded products, BLOOM and Auralief, establishing a robust plug and play online sales presence for existing and upcoming Love Pharma products
  • The online platform seamlessly integrates social media and digital marketing capabilities for sales and marketing campaigns

Love Pharma Co. ("LOVE" and or "The Company") (CSE:LUV)(FSE:G1Q0), the Company is excited to announce the launch of the Love Pharma online shop, a fully integrated e-commerce platform featuring its proprietary products, BLOOM and Auralief, now available to purchase at https:lovepharmashop.com

"This proprietary online store will be deployed for LOVE's over-the-counter therapeutics arm, for which the Company has 6 exclusive licenses, as previously announced," said Mr. Joshua Maurice, LOVE's Chief Operating Officer. "During the initial soft-launch phase, we are focused on direct-to-consumer sales, supported by integrated social media and digital marketing campaigns. The second phase of B2B sales will build on the success of our B2C marketing and awareness strategies. We are constantly assessing results to establish the most effective B2B launch using our proprietary e-commerce platform."

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Psychedelics Stocks to Watch (Updated 2022)

Psychedelics Stocks to Watch (Updated 2022)

The small-cap market has been invaded by a flurry of psychedelics stocks to watch thanks to new company launches. Investors now have a variety of options for taking a run in the shroom stocks space.

In an effort to expand the capabilities of the medical field, companies are starting to investigate the potential of psychedelic medicines and are looking to raise capital in the public market.

While this industry is still in its early stages, the promising potential of psychedelic medicine drug products has attracted the interest of savvy investors eager for an emerging investment opportunity.

Keep reading...Show less

COMPASS Pathways to participate in upcoming Jefferies Innovation in Mental Health Summit

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will hold a fireside chat at Jefferies Innovation in Mental Health Summit at 8:30am ET on 22 September 2022.

A live audio webcast of the fireside chat will be accessible from the "Events" page of the Investors section of the COMPASS website. Each replay of the webcast will be accessible for 30 days following each event. For more information, please visit ir.compasspathways.com

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Awakn Life Sciences Reports Strong Q2 2022 Results

Awakn Life Sciences Reports Strong Q2 2022 Results

Awakn delivered revenue growth of 34% in Q2

Awakn also announces closing of first tranche of private placement financing

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×